Litigation Details for Novartis Pharmaceuticals Corporation v. Mylan Pharmaceuticals Inc. (N.D.W. Va. 2019)

« Back to Dashboard

Novartis Pharmaceuticals Corporation v. Mylan Pharmaceuticals Inc. (N.D.W. Va. 2019)

Docket		Date Filed	2019-10-30
Court	District Court, N.D. West Virginia	Date Terminated	2024-02-26
Cause	35:271 Patent Infringement	Assigned To	Thomas Shawn Kleeh
Jury Demand	None	Referred To
Patents	8,101,659; 8,796,331; 8,877,938; 9,388,134
Link to Docket	External link to docket

Details for Novartis Pharmaceuticals Corporation v. Mylan Pharmaceuticals Inc. (N.D.W. Va. 2019)

Date Filed	Document No.	Description	Snippet	Link To Document
2019-10-30				External link to document
2019-10-30	114	Other Document	and March 1, 2023 trial of U.S. Patent Nos. 8,877,938 and 9,388,134 in this matter, the parties…October 2019 30 March 2020 1:19-cv-00201 Patent - Abbreviated New Drug Applications (ANDA)	External link to document

Novartis Pharmaceuticals v. Mylan Pharmaceuticals, 1:19-cv-00201: Entresto Patent Litigation Analysis

Last updated: September 25, 2026

Novartis Pharmaceuticals Corporation sued Mylan Pharmaceuticals Inc. in the U.S. District Court for the District of Delaware after Mylan submitted an abbreviated new drug application seeking approval for a generic version of Entresto, Novartis’s sacubitril/valsartan product. The case was a Hatch-Waxman Paragraph IV action involving Entresto patents listed in the FDA Orange Book. The litigation ended without a published merits decision determining patent validity or infringement. Publicly available records do not disclose the material commercial terms of the parties’ resolution.

What drug was at issue in Novartis v. Mylan, 1:19-cv-00201?

The case concerned Entresto, a fixed-dose combination of sacubitril and valsartan.

Item	Detail
Brand	Entresto
Active ingredients	Sacubitril and valsartan
Dosage form	Oral tablets
Therapeutic category	Heart failure and cardiovascular disease
Innovator	Novartis Pharmaceuticals Corporation
Generic applicant	Mylan Pharmaceuticals Inc.
Court	U.S. District Court for the District of Delaware
Civil action	No. 1:19-cv-00201
Judge	Richard G. Andrews
Filing date	February 1, 2019
Legal pathway	Hatch-Waxman patent litigation
Regulatory trigger	Mylan ANDA and Paragraph IV certification

Entresto combines sacubitril, a neprilysin inhibitor, with valsartan, an angiotensin II receptor blocker. The product received FDA approval in 2015 for specified heart-failure indications and became one of Novartis’s principal cardiovascular products. [1]

What patents protected Entresto in the Mylan litigation?

The litigation involved patents listed for Entresto in the FDA Orange Book, including U.S. Patent Nos. 8,877,938 and 9,066,856. The patents covered aspects of the sacubitril/valsartan combination and its pharmaceutical use.

Patent	General subject matter	Relevance
U.S. 8,877,938	Sacubitril/valsartan pharmaceutical composition	Core combination-product protection
U.S. 9,066,856	Sacubitril/valsartan pharmaceutical composition and related use claims	Orange Book-listed protection asserted against ANDA applicants
Related continuation patents	Additional composition, formulation, or method claims	Potential later-entry barriers depending on listing and enforceability

The precise claim scope must be assessed against the asserted claims and Mylan’s ANDA product description. A patent’s inclusion in the Orange Book does not establish infringement, validity, or enforceability. It creates the statutory framework for notice and patent litigation when an ANDA applicant files a Paragraph IV certification. [2]

Why did Novartis sue Mylan?

Mylan’s ANDA included a Paragraph IV certification stating that the relevant Entresto patents were invalid, unenforceable, or would not be infringed by Mylan’s proposed generic product. Novartis responded by filing suit within the 45-day statutory period.

Under the Hatch-Waxman Act, a timely infringement action generally triggers a 30-month stay of FDA approval, subject to statutory exceptions and court orders. The stay protects the innovator from immediate approval while the patent dispute proceeds, but it does not guarantee that the patents will survive challenge or that generic entry will be delayed until patent expiry. [3]

The key legal issues were:

1. Whether Mylan’s proposed sacubitril/valsartan tablets fell within the asserted patent claims.
2. Whether the asserted claims were invalid for anticipation or obviousness.
3. Whether any asserted patent was unenforceable.
4. Whether Novartis could obtain an injunction or other relief preventing FDA approval or commercial launch.

What was the litigation status and outcome?

The action did not produce a reported district-court trial opinion resolving the principal patent issues. The public docket reflects resolution and closure rather than a published final judgment on validity or infringement.

The practical result is important:

• There was no publicly reported finding that Mylan’s product infringed.
• There was no publicly reported invalidity judgment against the asserted Entresto patents in this action.
• The docket does not provide the full commercial terms of the parties’ resolution.
• Any Mylan launch date or authorized-generic arrangement cannot be determined solely from the publicly available case docket.

A stipulated dismissal or settlement ending a Hatch-Waxman case does not establish that either side prevailed on the merits. It normally reflects a negotiated allocation of launch, patent, and commercial risk.

Did Mylan file a Paragraph IV challenge?

Yes. The case was initiated as a Paragraph IV ANDA dispute. Mylan’s certification put Novartis on notice that Mylan intended to seek FDA approval before the relevant patents’ expiration dates.

A Paragraph IV certification is a litigation position, not a final ruling. It can lead to:

• Patent infringement litigation.
• A 30-month FDA approval stay.
• Settlement negotiations.
• A permitted launch date before or after patent expiry.
• An authorized-generic or license arrangement.
• Continued litigation involving continuation patents or later-listed patents.

The case record does not establish that Mylan obtained a final court ruling authorizing an at-risk launch.

When did Entresto lose exclusivity?

Entresto’s exclusivity was controlled by several overlapping forms of protection.

Regulatory exclusivity

Entresto received new chemical entity-related FDA exclusivity in connection with its 2015 approval. That regulatory exclusivity expired before the later patent disputes and did not independently prevent Mylan from filing an ANDA by 2019.

The product’s commercial protection therefore depended primarily on patent rights and any settlement restrictions.

Patent exclusivity

The principal Orange Book-listed Entresto patents were associated with expiration dates in the mid-2020s, subject to patent-term adjustment, patent-term extension, pediatric exclusivity, terminal disclaimers, and any later-listed patents.

The relevant commercial question was not simply the nominal expiration date. It was whether:

• The patent claims survived invalidity challenges.
• The generic product practiced the claims.
• A settlement permitted an earlier launch.
• Later continuation or formulation patents created additional barriers.
• The FDA approved the ANDA after statutory stays and regulatory review.

Exclusivity timeline

Date	Event
2015	FDA approved Entresto
February 1, 2019	Novartis filed the Delaware action against Mylan
2019 onward	Hatch-Waxman litigation and settlement discussions
2020s	Core Entresto patent barriers approached expiration or settlement-defined launch windows
Post-resolution	Generic-entry timing depended on the settlement, FDA approval, and remaining patent rights

The case should not be treated as establishing a universal Entresto generic-entry date for all applicants. Other ANDA applicants could have different certifications, settlement terms, litigation outcomes, or product formulations.

What was the Orange Book status of Entresto?

Entresto was protected by Orange Book-listed patents directed to the sacubitril/valsartan combination and related pharmaceutical claims. Orange Book listing enabled Novartis to initiate infringement litigation based on an ANDA Paragraph IV certification.

Orange Book status affects FDA approval timing but does not resolve the underlying patent dispute. The FDA generally does not adjudicate patent validity or infringement. Those questions are decided through federal-court litigation or negotiated settlement. [2]

For commercial diligence, the relevant review should include:

• Current Orange Book patent listings.
• Patent expiration and pediatric-exclusivity dates.
• Any delisting or correction history.
• The ANDA applicant’s certification for each listed patent.
• Court orders affecting the 30-month stay.
• Settlement documents and FDA approval status.

How strong was Novartis’s Entresto patent estate?

The estate was commercially significant but not uniformly strong across every possible claim.

Strengths

The combination of sacubitril and valsartan created a product-specific protection strategy. Composition claims can be difficult for a generic applicant to avoid if the ANDA product contains the same active ingredients in the claimed relationship or dosage form.

Novartis also had multiple patents and continuation filings. That structure increased litigation complexity and allowed the company to assert different claim types against different generic products.

Vulnerabilities

The patents were exposed to conventional Hatch-Waxman defenses:

• Obviousness based on prior pharmaceutical combinations.
• Anticipation by earlier disclosures.
• Claim-construction disputes.
• Noninfringement arguments based on formulation or labeling differences.
• Enablement and written-description challenges.
• Enforceability defenses.

The absence of a published merits decision in this case means the docket does not provide a judicial assessment of the strength of the asserted claims against Mylan’s specific product.

What formulations and methods of use were protected?

The Entresto patent estate included protection directed to the sacubitril/valsartan combination and pharmaceutical use. Formulation-focused claims can address:

• The active-ingredient combination.
• Relative amounts or dosage ratios.
• Tablet composition.
• Pharmaceutical excipients.
• Dosage forms.
• Treatment of heart failure or related cardiovascular conditions.

Method-of-use claims can be commercially important because an ANDA applicant may seek approval for a label that overlaps with a patented indication. A generic applicant may attempt a section viii statement, also called a skinny label, to carve out a patented use. That strategy depends on whether the remaining label still induces infringement.

Did the case create biosimilar risk?

No. Entresto is a small-molecule drug, not a biologic. The relevant competitive threat was an ANDA-approved generic, not a biosimilar filed under the Biologics Price Competition and Innovation Act.

The distinction matters:

Issue	Entresto
Product category	Small-molecule combination drug
FDA pathway	ANDA
Challenge mechanism	Paragraph IV certification
Regulatory competitor	Generic
Biosimilar framework	Not applicable
Core legal statute	Hatch-Waxman Act

Which companies challenged Entresto patents?

Mylan was one of several generic companies associated with Entresto patent challenges and related litigation. Novartis’s broader patent strategy involved defending the product against multiple ANDA applicants.

The competitive landscape included generic manufacturers that could challenge:

• The same composition patents.
• Different patent claims based on the applicant’s formulation.
• Method-of-use patents.
• Later-issued continuation patents.
• Patents with different expiration dates.

Each applicant’s risk profile depended on its ANDA formulation and certification. A settlement with Mylan did not necessarily resolve every other applicant’s dispute.

What commercial exposure did Entresto create for Novartis?

Entresto generated substantial global revenue and was a major Novartis growth product. Generic entry risk therefore affected:

• Revenue forecasts.
• Cardiovascular portfolio valuation.
• Novartis’s margin profile.
• Royalty and licensing assumptions.
• Generic pricing scenarios.
• Investor estimates of post-patent erosion.

For a product with high sales, even a limited launch acceleration can materially reduce revenue. The key variables were the number of approved generic suppliers, launch timing, generic discounting, authorized-generic participation, and the extent of substitution in U.S. pharmacy channels.

What patent litigation affected generic launch risk?

The Mylan action created a litigation barrier, but it did not by itself determine the final launch date. Generic launch risk depended on four separate events:

1. FDA approval of Mylan’s ANDA.
2. Expiration or removal of the applicable 30-month stay.
3. Resolution of the asserted patents.
4. Any settlement-imposed launch restriction.

An at-risk launch before patent expiry would have exposed Mylan to damages and injunctive relief if Novartis prevailed. A licensed launch would have reduced infringement exposure but could have required royalties, delayed entry, or other commercial restrictions.

Key Takeaways

• Novartis Pharmaceuticals sued Mylan in the District of Delaware over a Paragraph IV ANDA challenge to Entresto.
• The product was sacubitril/valsartan, a small-molecule cardiovascular combination, so biosimilar law did not apply.
• The action involved Orange Book-listed Entresto patents, including U.S. Patent Nos. 8,877,938 and 9,066,856.
• The case ended without a published merits ruling establishing infringement or invalidity.
• Public docket materials do not disclose the material commercial terms of the parties’ resolution.
• Entresto’s generic-entry risk depended on patent expiration, FDA approval, the 30-month stay, and any settlement-defined launch date.
• The case should be analyzed alongside other Entresto ANDA litigations and later continuation or formulation patents.

FAQs About Novartis Pharmaceuticals v. Mylan Pharmaceuticals

Was Novartis v. Mylan an ANDA lawsuit?

Yes. It was a Hatch-Waxman action arising from Mylan’s ANDA and Paragraph IV certification concerning a generic version of Entresto.

Did Mylan win the Entresto patent case?

The public record does not show a published merits judgment awarding Mylan a ruling of invalidity or noninfringement. The action was resolved without a reported trial decision.

Did the case invalidate Entresto patents?

No reported decision in this action invalidated the asserted Entresto patents.

Is Entresto protected by formulation patents?

Entresto’s patent estate included composition and related pharmaceutical claims. The scope and enforceability of any formulation-specific claim must be evaluated patent by patent and against the ANDA product.

Does the case determine when generic Entresto launched?

No. The case provides litigation history but does not, by itself, establish a universal generic launch date. Launch timing depends on FDA approval, settlement terms, and remaining patent rights.

References

1. Novartis Pharmaceuticals Corporation. (2015). Entresto prescribing information. U.S. Food and Drug Administration.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Center for Drug Evaluation and Research.

3. 21 U.S.C. § 355(j).

4. Novartis Pharmaceuticals Corporation v. Mylan Pharmaceuticals Inc., No. 1:19-cv-00201, U.S. District Court for the District of Delaware. (2019–2020). Court docket.